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Abstract
Numerous studies have linked severe stress to the development of major depressive disorder 
(MDD), and suicidal behaviors. Furthermore, recent preclinical studies from our laboratory and 
others have demonstrated that in rodents, chronic stress and the stress hormone cortisol has caused 
oxidative damage to mitochondrial function and membrane lipids in the brain. Mitochondria play a 
key role in synaptic neurotransmitter signaling by providing adenosine triphosphate (ATP), 
mediating lipid and protein synthesis, buffering intracellular calcium, and regulating apoptotic and 
resilience pathways. Membrane lipids are similarly essential to central nervous system (CNS) 
function, because cholesterol, polyunsaturated fatty acids, and sphingolipids form a lipid raft 
region, a special lipid region on the membrane that mediates neurotransmitter signaling through G-
protein coupled receptors and ion channels. Low serum cholesterol levels, low antioxidant 
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capacity, and abnormal early morning cortisol levels are biomarkers consistently associated with 
both depression and suicidal behaviors. In this review, we summarize the manner in which 
nutrients can protect against oxidative damage to mitochondria and lipids in the neuronal circuits 
associated with cognitive and affective behaviors. These nutrients include ω3 fatty acids, 
antioxidants (vitamin C and zinc), members of the vitamin B family (Vitamin B12 and folic acid) 
and magnesium. Accumulating data have shown that these nutrients can enhance neurocognitive 
function, and may have therapeutic benefits for depression and suicidal behaviors. A growing body 
of studies suggests the intriguing possibility that regular consumption of these nutrients may help 
prevent the onset of mood disorders and suicidal behaviors in vulnerable individuals, or 
significantly augment the therapeutic effect of available antidepressants. These findings have 
important implications for the health of both military and civilian populations.
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INTRODUCTION
Chronic severe stress has been directly implicated in the pathogenesis of depression 
(Charney and Manji, 2004), and suicidal behaviors (Robinson et al., 2009). In United States 
(US) military populations, the suicide rate has been found to correlate with the frequency of 
deployment, suggesting that the prolonged exposure to stress levels may play a role (Bryan, 
2010). Historically, suicide rates for active duty military personnel in the US and in other 
industrialized countries were lower than suicide rates for the general population—usually 
less than half (Rothberg et al., 1990). However, studies over the last decade have described 
rising suicide rates in the US military populations (Lineberry, 2009), a finding that has lent 
increasing urgency to both military and civilian efforts at suicide prevention.
It has been well-established that the hypothalamic-pituitary-adrenal (HPA) axis is activated 
during stress, with increased levels of the stress hormone cortisol. For instance, cortisol 
serum levels are elevated in many depressed patients, and the dexamethasone suppression 
test (DST) did not inhibit serum cortisol levels (Sher, 2007). Patients with Cushing’s disease, 
which is characterized by high cortisol levels, commonly develop depressive symptoms 
(Wolkowitz et al., 2001). Altered morning cortisol levels have also been noted in individuals 
who attempted suicide (Sher, 2007). Moreover, it is noteworthy that "depression" in the 
sense of a low mood is a symptom of many vitamin/mineral deficiencies (e.g. Folic acid, 
vitamin C, magnesium.) (Bourre, 2004). Therefore, it is important to prevent depressive 
episodes due to vitamin/mineral deficiency, particularly for people under high levels of 
stress. The role of nutrients in the treatment of depression and suicidal behaviors has been 
extensively studied in the civilian population (Cocchi et al., 1980, Papakostas et al., 2005, 
Enya et al., 2004, Li and Zhang, 2007, Sowa-Kucma et al., 2008). Whether or not the 
nutrients may help as a strategy for the prevention or adjunctive treatment of depression or 
suicidal ideation in the military and civilian population remains underexplored.
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Recent preclinical and clinical studies have shown that chronic severe stress causes oxidative 
damage to mitochondrial function and to membrane lipids, resulting in aberrant 
neurotransmitter signaling and information processing in synapses and circuits mediating 
affective, cognitive, motoric, and neurovegetative behaviors (Shelton, 2007). We begin this 
review by describing the relevant evidence linking disrupted mitochondrial function, 
membrane lipids, and neurotransmitter signaling with depression, and suicidal behaviors. 
We then summarize the clinical research data demonstrating that specific nutrients that act to 
protect mitochondria and neurotransmitter signaling are involved in the pathogenesis and 
treatment of these disorders. These nutrients include ω3 fatty acids, antioxidants, B family 
vitamins, and magnesium. Finally, we discuss the preclinical and clinical evidence that 
regular use of these nutrients may have preventive effects in the treatment of depression or 
suicidal behavior.
STRESS AND SLEEP DEPRIVATION CAUSE OXIDATIVE DAMAGE TO 
MITOCHONDRIAL FUNCTION AND LIPID COMPOSITION, LEADING TO 
IMPAIRED NEUROTRANSMITTER SIGNALING
Stress and altered HPA axis activity have been shown to increase oxidative damage and 
reduce antioxidant defense (Epel, 2009, Irie et al., 2005, McIntosh and Sapolsky, 1996, 
Wolkowitz et al., 2008). Oxidative stress occurs when the production of oxygen-free radicals 
exceeds the capacity of antioxidants to neutralize them (McIntosh and Sapolsky, 1996). 
After chronic severe stress, in vivo glutathione (GSH, decrease of which is an indicator for 
oxidative stress) levels were found to be depleted, suggesting a state of oxidative stress 
(Madrigal et al., 2001). The study further noted that mitochondrial function was also 
reduced after chronic stress. Inhibiting GSH depletion by aminoguanidine (a nitric oxide 
synthase inhibitor) protected against the mitochondrial dysfunction induced by chronic 
stress (Madrigal et al., 2001). In addition, lipids in the brain are particularly vulnerable to 
oxidative stress, which has been found to induce lipid peroxidation, and leads to degradation 
of polyunsaturated fatty acids (PUFAs) (Arts et al., 2007, Virmani et al., 2005). Taken 
together, the evidence suggests that oxidative damage induced by chronic stress may cause 
mitochondrial dysfunction and reduce lipid production (including PUFAs).
Accumulating research also shows that sleep deprivation is a neurobiological stressor that 
causes oxidative damage in the brain (Lavie, 2009, McEwen, 2006). Other studies 
demonstrated that antioxidant capacity was decreased in peripheral tissues after sleep 
deprivation (Everson et al., 2005).Indeed, it has been proposed that one of the biological 
functions of sleep may be to protect against oxidative stress (Wolf et al., 2007). There is 
extensive and well-known literature on long-term disrupted sleep cycles as a precipitant for 
mood disorders (Wirz-Justice, 2006), and given the disrupted sleep cycle that many soldiers 
and trainees experience (e.g., during basic training, deployment, or military missions), this 
stressor may be of particular importance in military populations (van Liempt et al., 2006).
Oxidative stress, homocysteine (a neurotoxin for mitochondrial function) increases, and 
glucocorticoid receptor trafficking all affect mitochondrial function during chronic stress. 
High ROS (superoxide, hydrogen peroxide, and hydroxyl radical) levels damage 
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mitochondrial function (Jou et al., 2009, Madrigal et al., 2001, Sorce and Krause, 2009). It 
has been shown that p66Shc is a proapoptotic protein involved in ROS production in 
mitochondria leading to mitochondrial damage and apoptosis under oxidative or genotoxic 
stress conditions such as H2O2 or UV exposure. (Calabrese V, et al., 2010). Moreover, in 
both acute and chronic stress animal models, the homocystenine levels were significantly 
increased (Black and Garbutt, 2002, de Souza et al., 2006, Taqliari et al., 2010). The 
molecular mechanism(s) for homocysteine increase induced by the chronic stress remains 
unclear. Notably, some studies have suggested a link between high homocysteine 
concentrations and increased risk of depression (Almeida et al., 2004, Almeida et al., 2008). 
Recent studies have similarly shown that the stress hormone corticosterone directly 
modulates mitochondrial function (Du et al., 2009). While brief increase of corticosterone 
enhanced mitochondrial function, high doses or long-term administration decreased levels of 
the glucocorticoid receptor and neuroprotective molecule B-cell lymphoma 2 (Bcl-2) in 
mitochondria. Similar results were found in rats exposed to a chronic stress paradigm (Du et 
al., 2009).
Mitochondria are key regulators of neurotransmitter signaling at dendrites and synapses. 
They mediate important and diverse cellular functions in the central nervous system (CNS), 
including adenosine triphosphate (ATP) production, synaptic protein expression, lipid 
synthesis, intracellular calcium buffering, resilience, and apoptosis (Quiroz et al., 2008, 
Zundorf and Reiser, 2011). Especially in remote axons, dendrites, and synapses, 
mitochondria function as a “local government” to synthesize energy ATP, lipids, and 
proteins; provide substrates for lipid synthesis; maintain calcium homeostasis; and modulate 
apoptotic pathways to determine resilience and atrophy (Quiroz et al., 2008, Zundorf and 
Reiser,2011). Cumulative evidence further shows that mitochondria are a key regulator of 
neurotransmitter signaling at the synapses (Ben-Shachar and Laifenfeld, 2004, Verstreken et 
al., 2005) and, in conjunction with synaptic calcium dynamics, play a very active role in 
regulating synaptic plasticity (Ben-Shachar and Laifenfeld, 2004, Brenner-Lavie et al., 2009, 
Mattson et al., 2008, Verstreken et al., 2005). For instance, mitochondrial transport is 
significantly increased in response to neuronal activity and is essential for enhancing 
synaptic strength (Mattson, 2007, Verstreken et al., 2005). In support of these findings, it has 
been suggested that the atrophy of hippocampal dendrites and synapses seen in response to 
chronic stress may be due to decreased mitochondrial function (Cook and Wellman, 2004, 
Pavlides et al., 2002).
Lipids are similarly particularly vulnerable to oxidative damage (Arts et al., 2007). Sixty 
percent of the wet weight of the mammalian brain comprises lipids. Approximately 70% of 
the fatty acid pool is made de novo, and 30% must be obtained through diet. Seafood, fish 
oils, and fortified foods are rich sources of ω–3 polyunsatuated fatty acids (ω–3 PUFAs: 
eicosapentaenoic acid (EPA), docosapentaenoic acid (DPAω–3), and docosahexaenoic acid 
(DHA)), as well as cholesterol. DHA comprises 14% of total fatty acids in the body and is 
concentrated in neuronal membranes and synapses (Brunner et al., 2002, Kunugi, 2001). The 
composition of lipids, including cholesterol and PUFAs, can be affected by both cellular 
function and diet. In this regard, oxidative stress has a large impact on lipid metabolism 
(including both cholesterol and PUFAs). Lipid peroxidation leads to oxidative lipid 
deterioration, which alters membrane permeability and fluidity and results in lipid 
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degradation (Delibas et al., 2004, Engstrom et al., 2009). Lipid peroxidation can be inhibited 
by antioxidants such as vitamin C and vitamin E, which protect lipids from oxidation (Frank 
and Gupta, 2005, Mahadik et al., 2001). Notably, levels of malondialdehyde (MDA), which 
is a byproduct of polyunsaturated lipid degradation by ROS, were found to be significantly 
increased in depressed patients (Bilici et al., 2001, Khanzode et al., 2003a, Sarandol et al., 
2007). Furthermore, studies have demonstrated that lower serum cholesterol and DHA levels 
are associated with suicide attempts (Brunner et al., 2001, Brunner et al., 2002).
The fatty acid composition of the human brain is the key to maintaining the structural and 
functional integrity of cellular membrane structures. Recent studies have demonstrated that 
one of the most important functions of cholesterol and DHA is to form lipid rafts—special, 
highly-ordered regions on the plasma membrane that are rich in cholesterol, DHA, and 
sphingolipids (Ferrer, 2009, Pani and Singh, 2009). Lipid rafts function to cluster receptors 
and proteins involved in signal transduction (e.g. G-protein subunits, adenylyl cyclase), aid 
in protein scaffolding, and facilitate internalization of G-protein coupled receptors (Ferrer, 
2009, Pani and Singh, 2009). A subset of lipid rafts containing caveolin proteins (known as 
Caveolae) play an important role in modulating synaptic plasticity and neurite outgrowth 
(Ferrer, 2009, Pani and Singh, 2009). As a major component of lipid rafts, DHA regulates 
dopaminergic and serotoninergic neurotransmission (Kodas et al., 2002, Zimmer et al., 
2000) and signal transduction (Vaidyanathan et al., 1994), and interacts with membrane-
bound enzymes (Bourre et al., 1989) and ionic channels (Vreugdenhil et al., 1996). Caveolae 
are widely expressed in the CNS in brain microvessels, endothelial cells, astrocytes, 
oligodendrocytes, Schwann cells, dorsal root ganglia, and hippocampal neurons (Allen et al., 
2007).
Investigators have suggested that neurotransmitter signaling may occur via clustering of 
receptors in lipid rafts or caveolae, and the effects of lipid rafts on neurotransmitter signaling 
have been implicated in neurological and psychiatric diseases in general (Nomura et al., 
2008, Pani and Singh, 2009), and in mood disorders in particular (Brambilla et al., 2003, 
Shiah and Yatham, 2000, Donati et al., 2008). Traditionally, the brain systems receiving the 
greatest attention in neurobiological studies of mood disorders were the monoaminergic 
neurotransmitter systems (e.g., the serotonergic, dopaminergic, and norepinephrinergic 
systems) that are extensively distributed throughout the network of limbic, striatal, 
hippocampal, and prefrontal cortical neuronal circuits (Drevets, 2000, Manji and Duman, 
2001, Nestler et al., 2002). However, recent studies show that glutamatergic synaptic 
plasticity may be the convergence point for the treatment of mood disorders, and alterations 
in this system are known to play a major role in cellular plasticity and resilience (Sanacora et 
al., 2008). Existing antidepressants and mood stabilizers have prominent effects on the 
glutamatergic system, and modulating glutamatergic, ionotropic, or metabotropic receptors 
results in antidepressant-like properties in animal models (Sanacora et al., 2008). The 
structurally dissimilar mood stabilizing agents lithium and valproate were both found to 
reduce synaptic expression of the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
(AMPA) glutamate receptor at synapses in vivo and in vitro in the hippocampus (Du et al., 
2008, Du et al., 2003, Du et al., 2004). In contrast, antidepressant agents such as 
imipramine, lamotrigine, and riluzole enhanced surface AMPA receptor expression and 
phosphorylation of GluR1S845 in the hippocampus in vivo (Du et al., 2007). As a result, 
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several glutamatergic modulators targeting various glutamate components are currently 
being studied in the treatment of mood disorders, including release inhibitors of glutamate, 
N-methyl-D-aspartate (NMDA) antagonists, AMPA throughput enhancers, and glutamate 
transporter enhancers (Sanacora et al., 2008). Preliminary pharmacogenetic studies have also 
strongly implicated glutamatergic signaling in suicidal behaviors (Lekman et al., 2008).
Taken together, these findings suggest that chronic stress damages mitochondrial function 
and subsequently changes the lipid composition in the brain. The altered lipid composition 
may have a large impact on the structural and functional integrity of the cellular membrane 
structure, ultimately leading to aberrant neurotransmitter signaling. This altered 
neurotransmitter signaling may in turn contribute to the pathophysiology of depression and 
suicidal behavior (Figure 1).
CURRENT HYPOTHESES REGARDING THE ETIOLOGY OF DEPRESSION 
AND SUICIDAL BEHAVIORS
Many hypotheses for the pathophysiology of depression and suicidal behaviors have been 
proposed, and it is beyond the scope of this article to review them all. However, it is 
interesting to note the large and varied literature on depression implicates (but is not limited 
to) many different etiologies to varying degrees, including dysfunction or alterations in 
monoamine neurotransmitters (serotonin, norepinephrine, and dopamine) (Bourin et al., 
2002, Owens, 2004, Syvalahti, 1987), oxidative stress (Maes et al.,2011), glutamatergic 
synaptic strength (Du et al., 2004, Du et al., 2007, Zarate and Manji, 2008), mitochondria 
(Rezin et al., 2008), cytokines (Maes et al., 2009b), homocysteine (Folstein et al., 2007), 
lipids (including cholesterol and PUFAs) (Su, 2009), neurotrophins or growth factors 
(Dwivedi, 2009, Molendijk et al., 2011), magnesium (Eby and Eby, 2010), zinc (Irmisch et 
al., 2010), cyclic AMP (cAMP) response element binding (CREB) (Czeh and Simon, 2005), 
and histone deacetylase (HDAC) (Covington et al., 2009). Finally, stress (Bao et al., 2008), 
sleep (Fang et al.,2010), altered neurotransmitter serotonin signaling (Brown and Gershon, 
1993, Nordstrom and Asberg, 1992), lipids (Brunner et al., 2002, Colin et al., 2003), and 
neurotrophins (Dwivedi, 2009) have all been proposed as key to the pathophysiology of 
suicidal behavior.
As regards the hypotheses presented in this paper, several common threads from this 
disparate literature emerge. For instance, accumulating evidence suggests that chronic stress 
and sleep deprivation increase cortisol levels (Wolkowitz et al., 2001), which in turn leads to 
oxidative stress (Madrigal et al., 2001) and high homocysteine levels (Black and Garbutt, 
2002, de Souza et al., 2006) and, subsequently, to mitochondrial damage (Madrigal et al., 
2001) and lipid degradation (Arts et al., 2007) in neuronal circuits. The lipid raft region is 
composed of cholesterol, polyunsaturated fatty acids (including EPA, DHA), and 
sphingolipids and mediates neurotransmitter signaling through G-protein coupled receptors 
and ion channels (Pani and Singh, 2009). It has been shown that depletion of cholesterol, or 
EPA and DHA caused a decrease in numbers of lipid raft on the neuronal membrane, which 
may lead to the aberrant G-protein coupled receptor signaling (Siddiqui et al., 2007). It is 
note-worthy that lower serum cholesterol and DHA levels are associated with suicide 
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attempts (Brunner et al., 2001, Brunner et al., 2002, Neaton et al., 1992). Drugs, which 
lower the cholesterol levels, are able to cause the depressive symptoms (Tatley and Savage, 
2007). In addition, fish-intake (rich in EPA or DHA) directly protects against the onset of 
major depressive disorder (Weidner et.al., 1992). Moreover, chronic stress induced an 
inhibition to the respiratory chain in the mitochondria in the brain (Madrigal et al., 2001). 
Mitochondrial dysfunction caused by changes in biochemical cascade or the damage to the 
mitochondrial electron transport chain has been suggested to be an important pathogenic 
factor for the psychiatric disorders, particularly in bipolar disorders and depression (Rezin et 
al., 2009). Moreover, food supplements, such as B12 or folate, which protects mitochondrial 
functions are effective as an adjunctive therapy for the treatment of depression (Papakostas 
et al., 2005). All these studies imply that mitochondrial dysfunction and reduced formation 
of lipid raft may be involved in the etiology of depression and suicidal behavior (Figure 1). 
These stress-induced neuronal dysfunctions interact with the other genetic and 
environmental factors, including adverse childhood events, exposure to trauma, drug abuse, 
smoking, alcohol usage, sleep, diet, and exercise levels, to precipitate mood disorders in 
genetically and/or physiologically vulnerable or predisposed individuals (Figure 1). The 
evidence reviewed here thus provides multiple targets for the treatment of mood and anxiety 
disorders. Below, we review evidence supporting the ability of several nutrients that are safe 
and widely-available over the counter to either prevent the onset of these conditions or 
augment the effects of currently available therapeutics.
OXIDATIVE STRESS, CHOLESTEROL, AND ω3 FATTY ACIDS IN THE 
PATHOPHYSIOLOGY AND TREATMENT OF DEPRESSION AND SUICIDAL 
BEHAVIORS
Depression and suicidal ideation are both accompanied by decreased antioxidant levels
Antioxidants are compounds that can quench free radicals by accepting an unpaired electron. 
In addition to the endogenous antioxidant enzyme systems, food contains many antioxidants, 
including vitamin E, vitamin C, beta-carotene, leutin, α-lipoic acid, coenzyme Q10 (Co-
Q10), lycopene, zeaxanthines, and selenium. Although results from large randomized trials 
of dietary interventions have yielded mixed results, a number of observational studies have 
revealed that antioxidants enhance CNS cognition and resilience, particularly in 
neurodegenerative and psychiatric disorders (Smith and Blumenthal, 2010). For instance, 
accumulating evidence has shown that MDD is associated with decreased antioxidant levels 
and with the induction of oxidative pathways (Ng et al., 2008, Sarandol et al., 2007). Other 
studies have noted that individuals with MDD have significantly lower plasma 
concentrations of a number of key antioxidants, including vitamin C, vitamin E, zinc, and 
Co-Q10 (Khanzode et al., 2003b, Maes et al., 2009a). One study suggested that lowered 
blood concentrations of zinc, CoQ10, vitamin E, vitamin C, and GSH might contribute to a 
lowered total antioxidant capacity (TAC), which was noted to be significantly lower in 57 
patients with MDD than in 40 healthy volunteers (Cumurcu et al., 2009). A significant and 
inverse correlation was also noted between TAC and severity of depression using the 
Montgomery-Asberg Depression Rating Scale (MADRS) (Galecki et al., 2009). Lower 
antioxidant enzyme activity (e.g. glutathione peroxidase (GPX)), is another feature of 
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depression(Ozcan et al., 2004) . It is interesting to note that MDA levels were found to be 
significantly higher in depressed patients, and may therefore serve as a biomarker for 
depression (Chang et al., 2009). Long-term stress also causes oxidative damage to DNA (Irie 
et al., 2005). One of the oxidative stress modifiers of DNA is 8—dehydroxyguanisine (8-
OH-dG); levels of this compound were positively associated with depressive symptoms (Irie 
et al., 2003).
Although the evidence to date is preliminary, levels of antioxidants, vitamins, and 
carotenoids have also been found to be lower in patients with a history of suicide attempts 
(Li et al., 2007). Investigators have speculated that lowered antioxidant capacity may impair 
protection against ROS, thus damaging fatty acids (Edwards et al., 1998, Maes et al., 1999). 
As noted above, PUFAs are particularly vulnerable to lipid peroxidation.
Lower ω3 fatty acid and serum cholesterol levels are associated with suicide attempts and 
MDD
Epidemiological studies have identified low fish (high in ω-3 fatty acid) consumption as a 
risk factor for mortality from suicide (Hibbeln and Salem, 1995, Hirayama, 1990, Sublette et 
al., 2006, Tanskanen et al., 2001). One study noted that frequent fish consumption (twice per 
week or more) significantly reduced the risk of depressive symptoms and of self-reported 
suicidal ideation (Tanskanen et al., 2001). A 17-year follow-up study of over 250,000 
Japanese subjects showed that people who ate fish daily had a lower risk of death from 
suicide (Hirayama 1990). In addition, several reports indicate that lower ω3-fatty-acid 
levels, including lower plasma EPA, and DHA, or EPA in red blood cells, predicted greater 
risk of suicide attempt (Hibbeln and Salem, 1995, Huan et al., 2004, Sublette et al., 2006). 
Because both cholesterol and DHA are major components of the lipid raft, it is possible that 
reduced cholesterol and ω3-fatty-acid levels may affect the formation of lipid rafts in the 
CNS, and subsequently reduce neurotransmitter signaling (Czysz and Rasenick, 2013). 
Notably, increased formation of lipid rafts in the membrane would facilitate serotonergic 
(Donati et al., 2008, Renner et al., 2007), dopaminergic (Villar et al., 2009), and 
glutamatergic (Francesconi et al., 2009, Ponce et al., 2008) neurotransmitter signaling; all of 
these play important roles in the pathophysiology and treatment of psychiatric disorders. 
Studies have noted that low cholesterol levels are associated with increased risk of suicide 
(Neaton et al., 1992) and that this association shows an inverse relationship with baseline 
total serum cholesterol (Lester, 2002, Lindberg et al., 1992). Other studies found that 
individuals who attempted suicide had significantly lower cholesterol levels than controls 
(Atmaca et al., 2002, Boston et al., 1996, Kim et al., 2002, Kunugi et al., 1997, Maes et al., 
1997a, Modai et al., 1994, Rabe-Jablonska and Poprawska, 2000, Sarchiapone et al., 2001, 
Takei et al., 1994). A postmortem study found that the brains of violent suicide completers 
had a lower grey-matter cholesterol content (Lalovic et al., 2007), and that a family history 
of suicidal behavior was more frequent among carriers of Smith–Lemli–Opitz syndrome, an 
autosomal recessive disorder characterized by abnormally low cholesterol levels (Lalovic et 
al., 2004).
Similarly, many studies have reported an association between low cholesterol levels and 
depression (Cadeddu et al., 1995, Lindberg et al., 1994, Maes et al., 1994, Morgan et al., 
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1993, Olusi and Fido, 1996, Suarez, 1999), including a large Finnish study involving over 
29,000 men (Partonen et al., 1999). Low cholesterol levels have been found to confer 
increased risk of MDD (Partonen et al., 1999), and to correlate with severity of depressive 
symptoms in samples of elderly men (Morgan et al., 1993), middle-aged women (Horsten et 
al., 1997), and depressed patients (Rabe-Jablonska and Poprawska, 2000, Rafter, 2001, 
Steegmans et al., 2000). Studying cholesterol in depression may also help identify factors 
that place these patients at risk for non-response to treatment (Sonawalla 2002). Relatedly, 
use of cholesterol synthesis inhibitor statins (functionally HMG-CoA reductase inhibitors), 
which lower serum cholesterol levels, has been associated with psychiatrically adverse 
reactions, particularly depression and memory loss (Tatley and Savage, 2007).
The role of antioxidants and members of the vitamin B family in enhancing cognition and 
resilience, and in the treatment of mood disorders
Human studies as well as animal models of depression provide evidence suggesting that 
oxidative damage is involved in treatment resistance and in the working mechanisms of 
antidepressant agents (Alpert et al., 2002, Papakostas et al., 2004). For instance, one recent 
clinical study found that N-acetyl-cysteine (NAC), a potent antioxidant that up-regulates the 
glutathione pathway, significantly augmented the clinical efficacy of antidepressants and 
mood stabilizers in individuals with bipolar disorder (Berk et al., 2008).
Vitamin C (ascorbate) is a water-soluble vitamin that can be oxidized (dehydroascorbate). 
Dehydroascorbate can be recycled to ascorbate through endogenous antioxidant enzymes 
and glutathione. Several studies found that taking a combination of vitamin C and vitamin E 
supplements enhanced cognitive function in the elderly (Morris et al., 2002, Pettenuzzo et 
al., 2002). Vitamin C was also associated with antidepressant effects in patients with 
depression, secondary to adrenocorticotropic hormone (ACTH) treatment (Cocchi et al., 
1980). It was effective as an adjunctive treatment to fluoxetine (Amr et al., 2013), and 
improved mood—as assessed by the penile-vaginal intercourse (FSI),—in healthy young 
adults (Brody, 2002).
Another key vitamin is folic acid, which cooperates with vitamin B12 to promote the 
regeneration of methionine from homocysteine. Homocysteine is toxic to mitochondrial 
function (Coppen and Bolander-Gouaille, 2005, Paul et al., 2004) and, as noted previously, 
higher homocysteine levels have been associated with depression. In addition, methionine 
can be converted to S-adenosylmethionine (SAMe), which is the principal methyl donor in 
the brain. Double-blind, clinical trials demonstrated that, when used adjunctively with 
standard selective serotonin reuptake inhibitors (SSRIs), SAMe had antidepressant effects in 
patients with MDD (Papakostas, 2009). Studies have linked lower folic acid levels to 
depression in elderly women (Ramos et al 2004), in a middle-aged community sample 
(Sachdev et al., 2005), and in male smokers (Sanchez-Villegas 2009). Vitamin B12 was 
similarly linked to depressive symptoms in women (Sanchez-Villegas 2009). In addition, 
folate depletion has been linked to disturbed metabolism of serotonergic and other biogenic 
amines. In studies of individuals with MDD treated with fluoxetine, low folate levels were 
associated with delayed onset of clinical improvement (Papakostas et al., 2005), as well as 
treatment resistance (Papakostas et al., 2004). Moreover, co-administration of methylfolate, 
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a highly absorbable form of folic acid, has been found to augment the effects of SSRIs 
(Coppen and Bailey, 2000, Godfrey et al., 1990, Roberts et al., 2007)
Zinc is another mineral with antioxidant properties (Powell, 2000), and accumulating data 
suggest a relationship between low serum zinc levels and severity of depression (Maes et al., 
1997b, Siwek et al.,2010). Zinc deficiency increases ROS, which could harm mitochondrial 
function (Corniola et al., 2008). Notably, various animal studies have demonstrated that zinc 
has antidepressant effects either alone or as an augmentation strategy for traditional 
antidepressants (Nowak et al., 2003, Sowa-Kucma et al., 2008). These effects are 
hypothesized to be related to zinc’s anti-oxidative properties, effects on PUFA metabolism, 
and neurogenesis stimulation through increased gene expression of brain-derived 
neurotrophic factor (BDNF) (Maes et al., 1997b, Siwek et al., 2010). A recent double-blind, 
placebo-controlled study of daily zinc supplementation to imipramine therapy in patients 
with MDD found that MADRS scores were significantly negatively correlated with serum 
zinc levels; furthermore, treatment-resistant patients with MDD had lower zinc 
concentrations than patients who were not treatment-resistant (Siwek et al., 2010).
Finally, magnesium is key to numerous enzymatic reactions involving the formation and use 
of ATP in energy metabolism. In addition, it is also a NMDA receptor blocker that controls 
calcium entry to the neurons (Eby and Eby, 2010). It is noteworthy that, in both animal 
studies and individuals with treatment-resistant MDD, the NMDA antagonist ketamine has 
rapid and long-lasting anti-depressant effects (Zarate et al., 2006). Case studies have noted 
that both iv (Enya et al., 2004) and oral magnesium were associated with rapid resolution of 
depressive symptoms secondary to various disorders, including MDD (Eby and Eby, 2006). 
In addition, in a double-blind randomized clinical trial, it was shown that magnesium was as 
effective as imipramine in treating depressive symptoms in elderly patients with Type II 
diabetes (Barragan-Rodriguez et al., 2008).
ω3 fatty acids in enhancing cognition and resilience, and treating mood disorders
One study found that increased fish intake, even combined with a cholesterol-lowering diet, 
decreased depressive symptoms (Weidner et al., 1992). Diverse studies—including 
epidemiological studies, case-control comparisons of blood and brain tissues, double-blind, 
randomized, placebo-controlled trials, and meta-analyses of these trials—have consistently 
indicated that low fish (high in ω-3 fatty acid) consumption or low ω3 body compositional 
status increases the risk of depression and other affective illnesses (Sinclair et al., 2007).
Both preclinical and clinical studies have shown that PUFA uptake enhances cognitive 
function (Richardson et al., 2003). Both local synthesis and uptake are thought to contribute 
to the brain pool of DHA; in animal studies, a DHA-and cholesterol enriched diet improved 
spatial learning in the Morris water-maze paradigm (Hooijmans et al., 2009). In humans, a 
double-blind, randomized, placebo-controlled study with one-way crossover (placebo to 
active treatment) reported improvements in reading, spelling, and behavior in children with 
developmental coordination disorder who received EPA, DHA, and γ-linolenic acid 
supplements (Richardson et al., 2003).
Du et al. Page 10
Crit Rev Food Sci Nutr. Author manuscript; available in PMC 2016 November 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The role of ω3 fatty acids in the treatment of depression has been extensive (see Table 1 for 
a summary). A recent meta-analysis of ω3 fatty acid treatment trials in depression that 
included data from more than twelve independent studies (Table 1) showed that consistent 
therapeutic benefits were associated with adjunctive use of the ω3 fatty acid EPA over 
placebo (Martins, 2009). Indeed, most of the clinical trials using predominantly 1–2g 
EPA/day exhibited significant beneficial effects in depression patients (Hallahan et al., 2007, 
Jazayeri et al., 2008, Mischoulon et al., 2009, Nemets et al., 2002, Peet and Horrobin, 2002, 
Su et al., 2003, Su et al., 2008a). However, several clinical trials using DHA or fish oil 
enriched with DHA showed no beneficial effect for treating MDD or perinatal depression 
(Freeman et al., 2008, Grenyer et al., 2007, Marangell et al., 2003, Rees et al., 2008, Silvers 
et al., 2005). The effectiveness of ω3 fatty acids has also been evaluated in the treatment of 
bipolar depression, where two of three placebo-controlled, double-blind trials found a 
beneficial effect over placebo (Clayton et al., 2009, Stoll et al., 1999). This effect may be 
related to the regulation of intracellular phospholipase A2 activity (Smesny et al., 2013). In 
addition, ω3 fatty acid treatment was also beneficial in the treatment of schizophrenia 
(Nakagome et al., 2009, Peet, 2003).
Studies have also evaluated the utility of ω3 fatty acids for preventing suicidal behaviors. In 
a randomized, double-blind, placebo-controlled trial of patients recruited from an emergency 
room who had exhibited recurrent self-harm behaviors, 2g/day of ω3 long chain fatty acids 
led to a 45% reduction in suicidal thinking, and a 30% reduction in depressive symptoms 
(Hallahan et al., 2007).
CONCLUDING REMARKS
This manuscript has summarized the existing evidence that ω3 fatty acids, antioxidants, B 
family vitamins, zinc and magnesium protect mitochondrial function and enhance 
neurotransmitter signaling in the brain. In addition, reduced ω3 fatty acids, oxidative 
capacity, B-12, and folic acid levels have been associated with both depression and suicidal 
ideation in humans. The question is the extent to which administration of these particular 
nutrients may exert beneficial effects on depressive symptoms or suicidal ideation. We have 
listed the components and side effects for the nutrients in Table 2.
While this is an issue of considerable importance for public health, it has particular urgency 
in military populations. Numerous recent studies have called for a way to address prevention 
and more effective treatment strategies for depression and suicidal ideation in both civilian 
and military populations. There appears to be a strong relationship between duration of 
combat exposure and the severity of mental illness (Dohrenwend, 2006), suggesting that the 
severity of stress may play a role. Specifically, repeated exposure to combat and multiple 
deployments might work as a repetitive severe stressor in this situation, in addition to being 
an “anticipatory stressor” (e.g, worrying about what will happen) as well as associated with 
physiological stressors (e.g., sleep deprivation) (Selby et al.,2010). Indeed, cumulative 
studies have shown that exposure to combat is a risk factor for both PTSD (Lapierre, 2008) 
and depression (Lapierre et al., 2007) in soldiers. Not surprisingly, injured soldiers also 
report more depressive and suicidal problems (McAllister, 2009). Furthermore, PTSD is 
strongly linked to suicidal behavior (Kessler, 2000). As reviewed above, psychological 
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repetitive stress, traumatic experience, and sleep deprivation were all shown to cause 
oxidative stress and mitochondrial damage in the brain (Du et al., 2009, Jou et al., 2009, Su 
et al., 2008b, Zhang et al., 2006). Most of the civilian clinical trials cited in this paper cover 
a wide age range including that of most soldiers.
The multiple nutrients reviewed here affect stress-related damage to mitochondrial function 
and neurotransmitter signaling at different levels in order to power a therapeutic benefit. 
Specifically, 1) the antioxidants vitamin C would increase oxidative status during stress, and 
zinc would enhance the antioxidant effect; 2) vitamin B12 and folic acid would reduce the 
level of the toxic homocysteine and enhance the formation of antidepressant SAMe; 3) the 
essential ω3 fatty acids would support the function of lipid rafts; and 4) magnesium would 
facilitate mitochondrial enzyme function and block the calcium entry from NMDA receptors 
(Figure 2). As noted above, previous studies have shown that antidepressant drug resistance 
is associated with low serum levels of folic acid (Papakostas et al., 2004), vitamin B12 
(Papakostas et al., 2004), magnesium (Eby and Eby, 2010) and antioxidant status (Maes et 
al., 2009a). Thus, these nutrients could be of considerable utility in either preventing the 
onset of mood disorders and suicidal behaviors in vulnerable individuals, or significantly 
augmenting the therapeutic effect of available drugs. Furthermore, because these nutrients 
are well known to be safe and reliable, implementing their use could be an easy way to 
protect individuals against stress-related psychiatric disorders, including PTSD, depression, 
and suicide attempts. Controlled clinical trials, both preventive and therapeutic, in both 
civilian and military populations, are warranted.
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Figure 1. Stress-induced damage to mitochondrial function and neurotransmitter signaling in 
the pathophysiology of PTSD, depression, and suicidal ideation
Chronic stress and sleep deprivation increase cortisol (which binds to its receptor, 
glucocorticoid receptor, GR) and corticotrophin releasing factor (CRF), followed by 
enhanced oxidative stress and higher homocysteine levels, which subsequently lead to 
mitochondrial dysfunction and lipid degradation in the neurons in the circuits mediating 
cognitive, affective, motoric, and neurovegetative functions. In addition, it was reported that 
chronic stress lead to down-regulation of neurotrophic factor brain-derived neurotrophic 
factor (BDNF) expression, which may also contribute to the chronic stress-induced neuronal 
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damage. Chronic stress also increases intracellular glutamate levels, which may cause 
altered calcium signaling and oxidative stress in the neurons. Glial cells include the 
astrocytes, oligodendrocytes, and microglia. Tripartite synapse represents the pre-synaptic 
structure, the post-synaptic structure and the surrounding astrocyte as a functional unit. 
Astrocytes sense and regulate synaptic activity depending on intracellular Ca2+ levels. 
Mitochondria provide trophic support, energy, and calcium-buffering capacity in the 
neuronal cell body, the astrocytes, the dendrites, and the synapses. Mitochondrial 
dysfunction and altered lipid rafts may lead to aberrant neurotransmitter signaling, dendritic 
atrophy, and neuronal endangerment. This stress-induced neuronal damage interacts with 
genetic and environmental factors, including adverse childhood events, exposure to trauma, 
drug abuse, smoking, alcohol use, sleep, diet, and exercise levels to eventually precipitate 
mental illness in vulnerable individuals. Depending on the severity of these factors, and an 
individual’s personal predisposition, the course of the illness may develop towards a variety 
of psychiatric disorders.
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Figure 2. Nutrients protect mitochondrial function and neurotransmitter signaling against 
stress-induced neuronal damage
Chronic stress causes increases of the cortisol level and the intracellular glutamate level in 
the brain. The high levels of cortisol may cause increased oxidative stress and higher 
homocy steine levels, which subsequently lead to mitochondrial dysfunction and lipid 
degradation. The in tra-cellular glutamate activates the N-methyl-D-aspartic acid receptor 
(NMDA R) and α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPA 
R) and induces calcium influx, which leads to hyperactivation of the Ca2+ dependent 
enzymes and oxidative stress. The higher level of lipid oxidation may result in lipid 
degradation and lower levels of Eicosapntemacnioc Acid (EPA), Docosahexaenoic Acid 
(DHA), or other polyunsaturated fatty acid (PUFA) in the brain for the formation of the lipid 
rafts, followed by a decrease in the number of lipid rafts, which may affect the G-protein 
coupled receptor signaling at the synapses. ω3 fatty acids, vitamin C, folic acid, vitamin 
B12, zinc, and magnesium protect mitochondrial function and neurotransmitter signaling. In 
particular, ω3 fatty acids facilitate the formation of lipid rafts, which mediate 
neurotransmitter signaling. Vitamin C and zinc balance stress-induced oxidative stress 
during chronic stress situations. Vitamin B12 and folic acid reduce homocysteine levels, and 
enhance the formation of S-adenosylmethionine (SAMe). Magnesium is a co-enzyme for 
energy production in the mitochondria. It is also an NMDA antagonist that blocks excessive 
calcium influx and protects neurons.
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Table 2
The safety and side effects of the nutrients.
Over-the-
counter
Nutrient
Effective
dose in the
clinical trials
Maximum
Safe Dose for
Long Term
Usage*
Side Effects*
ω3 fatty acid 1000mg EPA/day (Jazaveri 2008) One report says 21g/day No side effect.
Vitamin C 3000mg/day (Brody 2002) 2000mg/day No side effect. Large doses of vitamin C can deplete the 
body’s supply of copper. People with kidney stones or 
kidney failure and people taking ampicillin, 
indomethacin, alsalate, or tetracycline should consult 
their doctor.
Folic acid 500mcg/day (Coppen 2000) 400mcg/day No side effect.
Vitamin B12 500mcg/day (Almaida 2010) 3000mcg/day Oral Vitamin B12 has no side effects.
Magnesium 150–300mg/day(Eby 2006) 350mg/day No side effect is associated with this dose.
Zinc 25mg/day (Siwek 2010) 50mg/day under supervision High doses of zinc affect the absorption of iron and 
copper. Zinc should be taken with food to avoid irritating 
the stomach. People with liver damage or an intestinal 
disorder should consult their doctor before taking 
supplementary zinc.
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